Jazz Pharmaceuticals Financial Statements
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals revenue and earnings
In fiscal 2025, Jazz Pharmaceuticals generated $4.27 billion in revenue, up 4.9% from fiscal 2024, its 16th consecutive year of revenue growth. Jazz Pharmaceuticals reported a net loss of $356.1 million, compared with net income of $560.1 million a year earlier. Operating margin was -10.1%.
Diluted earnings per share came in at -$5.84, down from $8.65. Over the last 5 fiscal years, JAZZ's revenue has grown at a 12.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.27B | 4.07B | 3.83B | 3.66B | 3.09B | 2.36B | 2.16B | 1.89B | 1.62B | 1.49B |
| Revenue growth (YoY) | +4.88% | +6.12% | +4.78% | +18.26% | +30.91% | +9.34% | +14.32% | +16.82% | +8.79% | +12.32% |
| Operating Expenses | — | — | — | — | — | — | — | 1.28B | 1.09B | 896.32M |
| Research & Development | 782.74M | 884.00M | 849.66M | 590.45M | 505.75M | 335.38M | 299.73M | 226.62M | 198.44M | 162.30M |
| Selling, General & Admin | 1.81B | 1.39B | 1.34B | 1.42B | 1.45B | 854.23M | 736.94M | 683.53M | 544.16M | 502.89M |
| Operating Income | -430.24M | 716.63M | 578.58M | -65.53M | 170.28M | 378.07M | 532.37M | 614.84M | 528.84M | 591.65M |
| Interest Expense | — | — | 32.80M | 32.80M | 89.90M | 87.60M | 62.50M | 56.70M | 37.80M | 27.50M |
| Pretax Income | -627.86M | 470.35M | 297.93M | -372.78M | -112.84M | 275.10M | 454.30M | 529.46M | 441.12M | 532.45M |
| Income Tax | -272.44M | -91.43M | -119.91M | -158.65M | 216.12M | 33.52M | -73.15M | 80.16M | -47.74M | 135.24M |
| Net Income | -356.15M | 560.12M | 414.83M | -224.06M | -329.67M | 238.62M | 523.37M | 447.10M | 487.85M | 396.83M |
| Net Income growth (YoY) | -163.58% | +35.02% | — | — | -238.16% | -54.41% | +17.06% | -8.35% | +22.94% | +20.42% |
| EPS (Basic) | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 |
| EPS (Diluted) | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 |
| Shares Outstanding (Basic) | 60.98M | 61.84M | 63.29M | 62.54M | 59.69M | 55.71M | 56.75M | 59.98M | 60.02M | 60.50M |
| Shares Outstanding (Diluted) | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M | 56.52M | 57.55M | 61.22M | 61.32M | 61.87M |
| EBITDA | -388.64M | 749.43M | 608.98M | -35.23M | 196.98M | 396.77M | 547.67M | 630.04M | 541.94M | 603.45M |
| Operating Margin | -10.08% | 17.61% | 15.09% | -1.79% | 5.50% | 16.00% | 24.63% | 32.52% | 32.67% | 39.76% |
| Net Margin | -8.35% | 13.77% | 10.82% | -6.12% | -10.65% | 10.10% | 24.21% | 23.64% | 30.14% | 26.67% |
This table shows 10 annual periods of Jazz Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow JAZZ's reporting calendar. What is a income statement?